Larvol Delta - Brain-cancer-patients-display-appropriate-immune-responses-and-decreasing-tumor-biomarkers-in-AIVITA-biomedicals-phase-2-clinical-trial

ovapuldencel-T (AVOVA-1) - Caladrius, AiVita Biomedical

https://www.prnewswire.com/news-releases/brain-cancer-patients-display-appropriate-immune-responses-and-decreasing-tumor-biomarkers-in-aivita-biomedicals-phase-2-clinical-trial-300944686.html

Oct 24, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next